Questions on Valeda for AMD: Clinical Results
Regarding results using Valeda Photobiomodulation for dry AMD, we can look to the LIGHTSITE III study which led to FDA authorization. In that study, at 21 months, 61.5 percent of patients improved one line of vision or more, 23.1 percent improved two lines of vision or more and 4.4 percent improved three lines of vision or more. Stated differently, 89 percent of patients improved by at least one line of vision.
https://pubmed.ncbi.nlm.nih.gov/37972955/
Hi
. I added a link to that study to your post. That's encouraging information. - Lori (Team Member) One point of clarification, you linked the 13 month data set article for LIGHTSITE III, I was referencing the 21 month data set. The LIGHTSITE III study has generated many publications as followup time has increased, all the articles are readily accessible by members on the internet. Would you mind sharing that link? We always ask that members provide links when they cite other sources. Thanks so much! - Lori (Team Member)
The 21 month data, as referenced in LumiThera patient handouts (I can upload the handout but I am not sure if it violates the site rules) have been presented at multiple meetings but will not actually have been published until the next issue of Retina.
24 month LIGHTSITE III data shows a +6.2 letter gain (p=0.0036) with a decreased incidence of geographic atrophy (GA) vs. sham of 24 % (p=0.007) after treatment with the Valeda light delivery device (the only FDA-authorized treatment to improve vision in Age-related Macular Degeneration).
https://pubmed.ncbi.nlm.nih.gov/41791029/
